EP981 Cytoreductive surgery for tubo-ovarian carcinoma – a study of surgical outcomes with primary surgery

2019 ◽  
Author(s):  
Y Shahabuddin ◽  
R Daly ◽  
C Thompson ◽  
N Gleeson
Keyword(s):  
Ovarian Carcinoma ◽  
Cytoreductive Surgery ◽  
Surgical Outcomes ◽  
Primary Surgery

Cardiac index assessment using bioreactance in patients undergoing cytoreductive surgery in ovarian carcinoma

2013 ◽  
Vol 27 (6) ◽  
pp. 621-627 ◽  
Author(s):  
David Kober ◽  
Constantin Trepte ◽  
Martin Petzoldt ◽  
Rainer Nitzschke ◽  
Lena Herich ◽  
...  
Keyword(s):  
Cardiac Index ◽  
Ovarian Carcinoma ◽  
Cytoreductive Surgery

Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients

2021 ◽  
Author(s):  
Mukur Dipi Ray ◽  
Suryanarayana S.V. Deo ◽  
Lalit Kumar ◽  
Manish Kumar Gaur
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Cytoreductive Surgery ◽  
Advanced Ovarian Cancer ◽  
Advanced Stages ◽  
Selection For ◽  
Selection Of Patients ◽  
Selection Of

In cases of ovarian carcinoma, primary cytoreductive surgery (CRS) is the standard treatment up to stage IIIB, but patient selection for neoadjuvant chemotherapy (NACT) in selected cases is controversial. A total of 200 patients with advanced ovarian cancer were analyzed retrospectively, according to specific selection criteria. Primary CRS was performed in 95 patients (47.5%) and interval CRS after 3–6 cycles of NACT was performed in 105 patients (52.5%). After median follow-up of 35 months, 5-year overall survival was 53.7% in the upfront CRS group and 42.2% in the NACT group. Primary CRS is the standard in advanced stages of ovarian carcinoma, but in certain subset of patients, NACT is preferred. Identifying that group is challenging but feasible. Proper selection of patients is key to successful outcomes.

A case of protrusion of an intraperitoneal chemotherapy catheter through rectum

2005 ◽  
Vol 15 (1) ◽  
pp. 171-174 ◽  
Author(s):  
Y. Bilsel ◽  
E. Balik ◽  
D. Bugra ◽  
S. Yamaner ◽  
A. Akyuz
Keyword(s):  
Ovarian Carcinoma ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery

Bowel penetration of an intraperitoneal catheter occurred in a patient who had received a course of uncomplicated intraperitoneal chemotherapy for a persistent ovarian carcinoma. One month after the termination of chemotherapy, she presented with protrusion of a catheter through anus. At operation, the catheter was removed, the rectum was repaired primarily, and a cytoreductive surgery was performed.

Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 5058-5058
Author(s):  
D. S. Chi ◽  
Y. Sonoda ◽  
N. R. Abu-Rustum ◽  
C. S. Awtrey ◽  
J. Huh ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Carcinoma ◽  
Cytoreductive Surgery ◽  
Predictor Variables ◽  
Concordance Index ◽  
Disease Specific Survival ◽  
Stage Iiic ◽  
Term Survival ◽  
Accuracy Measure ◽  
Disease Specific

5058 Background: Nomograms have been developed for numerous malignancies to predict a specific individual’s probability of long-term survival based on known prognostic factors. To date, no prediction model has been developed for patients with ovarian cancer. The objective of this study was to develop a nomogram to predict the probability of 4-year survival after primary cytoreductive surgery for bulky stage IIIC ovarian carcinoma. Methods: Nomogram predictor variables included age, tumor grade, histologic type, preoperative platelet count, the presence or absence of ascites, and residual disease status after primary cytoreduction. Disease-specific survival was estimated using the Kaplan-Meier method. Cox proportional hazards regression was used for multivariable analysis. The Cox model was the basis for the nomogram. The concordance index was used as an accuracy measure, with bootstrapping to correct for optimistic bias. Calibration plots were constructed. Results: A total of 462patients with bulky stage IIIC ovarian carcinoma underwent primary cytoreductive surgery at our institution during the study period of 1/89 to 12/03, of whom 397 were evaluable for inclusion in the study. The median age of the study population was 60 years (range 22–87). The primary surgeon in all cases was an attending gynecologic oncologist. Postoperatively, all patients received platinum-based systemic chemotherapy. Ovarian cancer-specific survival at 4 years was 51%. A nomogram was constructed on the basis of a Cox regression model and the 6 predictor variables. This nomogram was internally validated using bootstrapping and shown to have excellent calibration with a bootstrap-corrected concordance index of 0.67. Conclusions: A nomogram was developed to predict 4-year disease-specific survival after primary cytoreductive surgery for bulky stage IIIC ovarian carcinoma. The nomogram utilizes 6 predictor variables that are readily accessible, assigns a point value to each variable, and then predicts the probability of 4-year survival based on the total point value for an individual patient. This tool should be useful for patient counseling, clinical trial eligibility determination, postoperative management, and follow-up. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document